ID | 52796 |
フルテキストURL | |
著者 |
Fujii, K
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg
Kurozumi, K
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg
Ichikawa, T
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg
Onishi, M
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg
Shimazu, Y
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg
Ishida, J
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg
Chiocca, EA
Brigham & Womens Hosp, Dept Neurosurg
Kaur, B
Ohio State Univ, Dept Neurol Surg, Dardinger Lab Neurooncol & Neurosci
Date, I
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg
ORCID
Kaken ID
publons
researchmap
|
抄録 | Oncolytic viral (OV) therapy has been considered as a promising treatment modality for brain tumors. Vasculostatin, the fragment of brain-specific angiogenesis inhibitor-1, shows anti-angiogenic activity against malignant gliomas. Previously, a vasculostatin-expressing oncolytic herpes simplex virus-1, Rapid Antiangiogenesis Mediated By Oncolytic virus (RAMBO), was reported to have a potent antitumor effect. Here, we investigated the therapeutic efficacy of RAMBO and cilengitide, an integrin inhibitor, combination therapy for malignant glioma. In vitro, tube formation was significantly decreased in RAMBO and cilengitide combination treatment compared with RAMBO or cilengitide monotherapy. Moreover, combination treatment induced a synergistic suppressive effect on endothelial cell migration compared with the control virus. RAMBO, combined with cilengitide, induced synergistic cytotoxicity on glioma cells. In the caspase-8 and -9 assays, the relative absorption of U87 Delta EGFR cell clusters treated with cilengitide and with RAMBO was significantly higher than that of those treated with control. In addition, the activity of caspase 3/7 was significantly increased with combination therapy. In vivo, there was a significant increase in the survival of mice treated with combination therapy compared with RAMBO or cilengitide monotherapy. These results indicate that cilengitide enhanced vasculostatin-expressing OV therapy for malignant glioma and provide a rationale for designing future clinical trials combining these two agents.
|
キーワード | cilengitide
glioma
oncolytic viral therapy
|
発行日 | 2013-08
|
出版物タイトル |
Cancer Gene Therapy
|
巻 | 20巻
|
号 | 8号
|
出版者 | Nature Publishing Group
|
開始ページ | 437
|
終了ページ | 444
|
ISSN | 0929-1903
|
NCID | AA12570566
|
資料タイプ |
学術雑誌論文
|
関連URL | http://ousar.lib.okayama-u.ac.jp/metadata/52519
|
言語 |
英語
|
著作権者 | © Nature Publishing Group
|
論文のバージョン | author
|
査読 |
有り
|
DOI | |
Web of Science KeyUT |